1. Introduction {#sec1}
===============

Xeroderma pigmentosum (XP) is an autosomal recessive cancer prone disease characterized by sensitivity to ultraviolet rays (UVR). XP patients are consequently predisposed to develop skin and eyes cancers \[[@B14]\]. This disease is caused by inherited mutations in DNA repair genes encoding proteins that protect cells from UV-induced damage. XP is genetically heterogeneous with seven XP complementation groups (XP-A to XP-G) defective in nucleotide excision repair (NER) pathway and an additional "variant" form (XP-V) with normal NER but a deficient translesional synthesis.

XP-V patients have a relatively milder phenotype with a late onset of symptoms and delayed progression. Typically, XP-V patients do not have ocular or neurological abnormalities \[[@B8]\]. Many studies suggest that this form of XP is underdiagnosed \[[@B10], [@B1]\]. Therefore, XP-V patients represent only 20 to 30% of all XP cases \[[@B21]\].

Cells from XP-V patients are extremely hypermutable after exposure to UV due to the deficiency of pol eta \[[@B13], [@B26]\]. The DNA polymerase eta (*η*) normally catalyzes translesion synthesis (TLS) by incorporating dAMP opposite thymine residues of a cyclobutane thymine dimer (CPD) \[[@B17], [@B18]\]. In the absence of pol eta, the highly error-prone pol iota undertakes this bypass function resulting in the accumulation of UV-induced mutations and an increase in the susceptibility to skin cancer \[[@B6], [@B9]\].

Pol eta is encoded by the*POLH* gene, the human homolog of yeast Rad30 \[[@B18]\]. Pol *η* plays an important role in preventing genome instability after UV or cisplatin-induced DNA damage \[[@B4]\]. Chemoresistance of cancer to cisplatin treatment is due in part to human Pol *η*. Crystal structures of hPol *η* complexed with intrastrand cisplatin identified a hydrophobic pocket as a potential drug target for reducing chemoresistance \[[@B28]\].

More than 60 mutations have been identified in the*POLH* gene in cell lines derived from XP-V patients from different geographic locations, mainly Russia-Armenia, Scotland, Lebanon, Iran, Belgium, France, Japan, USA, Europe, Asia, Cayman Islands, Turkey, Israel, Germany, Korea, Algeria, and Tunisia \[[@B8]--[@B1], [@B18], [@B11]--[@B25]\].

In our study, we surveyed*POLH* mutations in 16 Tunisian patients with late onset of XP in order to assess the causative mutations of this disorder and to develop a rapid molecular diagnostic test.

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

Sixteen suspected XP-V patients belonging to ten consanguineous Tunisian families originated from different regions of Tunisia were investigated ([Table 2](#tab2){ref-type="table"}). Their age was ranging from 4 to 50 years.

2.2. Methods {#sec2.2}
------------

Written informed consent was obtained from all available family members or from parents of minor children. Families were interviewed using a structured questionnaire to collect information about family history, consanguinity, affected members, and associated diseases. DNA was isolated from peripheral blood leukocyte using salting-out method \[[@B20]\] or Qiagen kit DNA extraction.

### 2.2.1. Genetic Analysis {#sec2.2.1}

To confirm linkage to*POLH* gene, available family members were genotyped using two polymorphic microsatellite markers spanning a 0.4 Mb interval near to*POLH* locus (cen-D6S207 and D6S1582 (*POLH*-)tel) as previously described \[[@B1]\]. Microsatellite markers were selected from the genetic maps available on NCBI browsers and the CEPH genotype database (<http://www.cephb.fr/en/cephdb/>) on the basis of their heterozygosity percentage and closeness to the*POLH* gene. Genotyping was performed as described elsewhere \[[@B29]\].

### 2.2.2. PCR Long-Range {#sec2.2.2}

On absence of amplification of*POLH* exon 10, long PCR was performed using the Expand Long Template PCR System Kit (Expand Long Range dNTPack 700 units/*μ*L Roche). PCR was performed using different primers ([Table 3](#tab3){ref-type="table"}). The PCR program included 92°C for 2 min, 10 cycles of 92°C for 10 sec, 60°C for 15 sec, 68°C for 10 min, and 20 cycles of the same program except that the extension step was extended by 20 sec per cycle. PCR products were run on 1% agarose gel with the DNA ladder 1 kb molecular size marker (GeneRulerTM).

### 2.2.3. Bioinformatic Analysis {#sec2.2.3}

As several genomic rearrangements are commonly caused by recombination events induced by repetitive elements present in the human genome, the genomic sequence of the*POLH* gene (NG_009252.1) was obtained and analyzed from chr6: 43578281 to 43581387 position corresponding to exon 9 to exon 11 region. Screening for repetitive elements was performed using the RepeatMasker software available at <http://www.repeatmasker.org/> ([Table 1](#tab1){ref-type="table"}).

### 2.2.4. Sequencing and Mutation Analysis {#sec2.2.4}

Long range PCR products were directly sequenced using the ABI 3130 Genetic Analyzer by two pairs of primers ([Table 3](#tab3){ref-type="table"}). Mutation analysis and breakpoints of the deletion were determined as the last nucleotide showing sequence identity between wild and mutated sequences ([Figure 3](#fig3){ref-type="fig"}).

### 2.2.5. Mutation Nomenclature {#sec2.2.5}

The genomic reference of the*POLH*gene NG_011763.1 was used to annotate the deletion according to the HGVS version 2.0 (Mutalyzer 2.0.beta-26).

3. Results {#sec3}
==========

3.1. Clinical Findings {#sec3.1}
----------------------

In this study, we investigated sixteen patients with late onset of XP features. These patients belong to ten consanguineous families from different Tunisian geographic areas ([Table 2](#tab2){ref-type="table"}). For all patients, skin hyperphotosensitivity to UVR began at a mean age of 4 years. The mean age at onset of the first skin cancer was 24 years. Nonmelanoma skin cancer (NMSC) occurred in only 10 patients. At least, 3 among them developed only basal cell carcinoma (BCC) and 5 developed squamous cell carcinoma (SCC) combined with BCC ([Table 2](#tab2){ref-type="table"}).

3.2. Genetic Analysis {#sec3.2}
---------------------

The genetic examination of XP-V patients was initially assessed through routine procedures, which involved genotyping of all consanguineous XP-V patients and available related individuals. Haplotype analysis showed homozygosity for the closest two markers to*POLH* gene, D6S1582 and D6S271, with a founder haplotype (129--188) in all investigated patients ([Figure 1](#fig1){ref-type="fig"}).

3.3. PCR Long-Range {#sec3.3}
-------------------

DNA samples from these patients repeatedly failed to yield PCR amplification products for exon 10. Therefore, we assumed the presence of a genomic deletion spanning exon 10 (del exon 10). As del exon 10 was previously described in Italian patient at the genomic DNA level with 2.7 Kb deletion \[[@B8]\], we first screen for this deletion. Therefore, screening of this deletion by PCR did not yield any amplification product confirming that there are different breakpoints involved in our XP-V patients. In order to identify the deletion size, we amplified the sequence between exon 9 and exon 11 using primers POLH10ΔF and POLH10ΔR showed in [Table 3](#tab3){ref-type="table"}. Long range PCR revealed *a* ≈ 6 kb product for XP-V patients versus *≈*10 kb in control individual corresponding to approximately 4 kb size deletion ([Figure 2](#fig2){ref-type="fig"}).

3.4. Bioinformatic Analysis {#sec3.4}
---------------------------

Screening of repetitive elements present in exon 9 to exon 11 using repeat masker software revealed that 51.44% (4814 pb) of the sequence was interspersed repeat sequences. Among them, 11 SINE Alu sequences spanned a region of 2908 bp (31.08% of all the sequence) and 3 LINE sequences spanned a region of 1789 bp (19.12% of all the sequence). These Alu sequences are predicted to promote the occurrence of large deletions ([Table 1](#tab1){ref-type="table"}).

3.5. Mutation Screening {#sec3.5}
-----------------------

In order to detect the breakpoints with accuracy, two internal primer pairs were designed to sequence introns 9 and 10 across the deletion ([Table 3](#tab3){ref-type="table"}). Direct sequencing and analysis of the 6 kb PCR product ([Figure 2](#fig2){ref-type="fig"}) of XPV17 and XPV91 patients using primers POLHdelF and POLHdelR revealed that both the 5′ and 3′ breakpoints were located within homologous Alu Sq2 (class SINE (short interspersed elements, family Alu)) elements in introns 9 and 10 of*POLH* gene ([Figure 3](#fig3){ref-type="fig"}). This deletion*POLH*NG_009252.1: g.32438_36363del3926led to the loss of exon 10 (c.1370-2567_1539+1188del3925). This mutation has likely resulted from Alu-Alu equal homologous recombination.

3.6. Screening of Deletion by PCR {#sec3.6}
---------------------------------

After identification of the deletion breakpoints in two patients (XPV91 and XPV17), we screened the following patients for this deletion by PCR using primers POLHdelF and POLHdelR showed in [Table 3](#tab3){ref-type="table"}. In all patients, we found a product of 500 pb versus 4500 pb in virtual PCR. We then confirmed the presence of the same breakpoints by direct sequencing.

For individuals at a heterozygous state, we confirmed their profiles by two PCRs. The presence of one allele of exon 10 was confirmed using XPV10F and XPV10R primers and the absence of exon 10 on the other allele was confirmed using POLHdelF and POLHdelR primers.

4. Discussion {#sec4}
=============

We report 16 cases with NMSC, BCC, and SCC that occurred with a mean delay of 24 years after XP diagnosis. Five of our patients (XPV6KE, XP18G XPV20G, XPV43-1, and XPV53Z) had been treated by skin radiotherapy ([Table 2](#tab2){ref-type="table"}). After cancer treatment, many NMSC appeared. For example, XPV6KE died after frontal tumor metastasis and XPV18G experienced a metastasis after recurrence on the right cheek. These consequences may be explained by the significant role of pol eta in cancer radiotherapy response. Pol eta-deficient cells are resistant to ionizing radiation. This radioresistance results from the increased reparation of double strand breaks by homologous recombination repair system (HR) \[[@B22]\]. While for chemotherapy, previous studies demonstrate that pol eta-deficient cells are very sensitive to cisplatin and oxaliplatin and particularly for agents which exert their activities by blocking DNA replication forks \[[@B3]\]. Among the roles of pol eta is repairing lesions induced by cisplatin. Consequently, systemic chemotherapy using cisplatin will attack healthy cells and induce novel cancers on absence of pol eta. This type of chemotherapy may be very dangerous for XP-V patients. Knowing this important role of pol eta, mutation screening of*POLH* gene in patients with SCC or BCC could have an impact in guiding treatment choice.

Previous studies showed two specific mutations (c.1568_1571delGTCA and c.660+1G\>A) in three XP-V Tunisian patients \[[@B1], [@B19]\]. Deletion of exon 10 has been previously described at the cDNA level in XP-V patients from different geographic origins. It was found at homozygous state in two Algerian (XP62VI and XP75VI) and in one American (XP139DC) and at heterozygous state in one Tunisian (XP28VI) XP-V patients \[[@B10], [@B2]\]. Also,*POLH* del exon 10 has been described at genomic level in one Italian patient with 2.7 Kb deletion occurring between two poly (T) sequences \[[@B8]\] and in one Algerian XP-V patient with 3.763 bp deletion \[[@B24]\]. We report here a novel breakpoint of del exon 10,*POLH*NG_009252.1: g.32438_36363del3926, that presents in 16 XP-V Tunisian patients belonging to 10 unrelated families. This deletion can be screened by a simple PCR without confirming by sequencing. This rapid tool may facilitate molecular investigation of XP-V patient.

This mutation is probably a founder variation because it was carried by a particular haplotype (129--188 or 129--186). Del exon 10 is common in the world and probably it may be due to different founder effects. Repetitive sequences are the primary candidates to generate stable abnormal secondary structures producing large deletion during replication \[[@B7]\]. Alu elements are normally located within introns and 3′ untranslated regions of genes, which are considered mutational "hotspots" for large gene rearrangements \[[@B5]\]. Large deletions in*POLH* gene have been previously described in exons 5 and 6 \[[@B10], [@B2]\]. Similar founder mutations in the*POLH* gene have been reported in other populations such as Japanese and Korean. Therefore, 87% of the Japanese XP-V patients shared one of the four founder mutations described in Japan \[[@B10], [@B16]\].

5. Conclusion {#sec5}
=============

The presence of this founder mutation, reported in our study, could simplify genetic screening of XP patients in Tunisian population by implementing presymptomatic tests and hence early UV protection. Before treatment of patients\' skin cancers, XP status should be verified to avoid cancer recurrence. It is also important to consider the possible existence of such large deletion at heterozygous state. Consequently, we propose systematic screening of this mutation in all XP-V patients by two PC reactions; the 1st will amplify exon 10, while the 2nd will amplify across deletion breakpoints. After confirmation at a large scale in XP Tunisian patients, the test will be proposed for patients from Southern Mediterranean and Middle East countries.
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![Pedigree and haplotype analysis for the XPV families (the disease haplotype is indicated by shading) and clinical photograph of each affected patient.](BMRI2014-256245.001){#fig1}

![Agar gel electrophoretic analysis of the PCR*POLH* gDNA of exon 10 and its intronic boundaries showed difference in the size between affected individuals (XPV17B-1 and XPV91) compared to healthy parents (XPV(P)) and a healthy control. (Marker: 1 kb DNA ladder molecular size marker (GeneRuler).)](BMRI2014-256245.002){#fig2}

![Characterization of the deletion breakpoints. (a) Electropherogram demonstrating the junction fragment resulting from the large deletion in the XP-V patients. Partial representation of introns 9 and 10 with the 35 bp breakpoint overlap framed in red. (b) Nucleotide sequence alignment of the genomic sequence of introns 9 and 10 of the*POLH* gene. Short vertical lines indicate matched bases between both introns. (c) Schematic representation of the deletion breakpoints and their flanking Alu Sq2 elements. (1) represents a normal gDNA fragment and (2) schematizes the mutated gDNA with a deletion of 3925 bp.](BMRI2014-256245.003){#fig3}

###### 

Sequence analysis of repetitive elements of the 9358 bp sequence of *POLH* gene: 43572521--43581878 using repeat masker Software.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  score   \% div.   \% del.   \% ins.   Query sequence                Position in query-   C\     Matching\   Repeat class/family   -Position in repeat (left) end begin   linkage                                       
                                                                                           +      repeat                                                                                                                 
  ------- --------- --------- --------- ----------------------------- -------------------- ------ ----------- --------------------- -------------------------------------- ----------------- ---------- ------ --------- ----
  1692    13.5      0.4       0.4       chr6:POLH:43572521+43581878   657                  893    \(8465\)    C                     AluJr                                  SINE/Alu          \(2\)      310    74        1

  2266    10.4      0.3       4.3       chr6:POLH:43572521+43581878   925                  1240   \(8118\)    C                     AluSq                                  SINE/Alu          \(9\)      304    1         2

  658     26.3      8.6       4.6       chr6:POLH:43572521+43581878   1267                 1581   \(7777\)    C                     L1MA8                                  LINE/L1           \(25\)     6266   5940      3

  2432    12.0      0.0       0.0       chr6:POLH:43572521+43581878   1644                 1944   \(7414\)    C                     AluSx1                                 SINE/Alu          \(10\)     302    2         4

  3529    14.9      6.9       4.2       chr6:POLH:43572521+43581878   1958                 2302   \(7056\)    C                     L1MB8                                  LINE/L1           \(0\)      6178   5821      5

  2464    10.8      0.0       0.0       chr6:POLH:43572521+43581878   2303                 2609   \(6749\)    C                     AluSc5                                 SINE/Alu          \(2\)      307    1         6

  3529    16.1      7.0       4.4       chr6:POLH:43572521+43581878   2610                 3080   (6278       C                     L1MB8                                  LINE/L1           \(342\)    5820   5323      5

  2287    9.2       5.5       0.0       chr6:POLH:43572521+43581878   3081                 3372   \(5986\)    \+                    AluSq2                                 SINE/Alu          1          308    \(5\)     7

  1739    17.8      10.7      1.8       chr6:POLH:43572521+43581878   3373                 3510   \(5848\)    C                     L1MB8                                  LINE/L1           \(829\)    5333   5170      5

  810     18.7      1.2       7.0       chr6:POLH:43572521+43581878   3744                 3909   \(5449\)    C                     AluJo                                  SINE/Alu          \(19\)     293    137       8

  535     29.6      9.7       1.4       chr6:POLH:43572521+43581878   3990                 4509   \(4849\)    \+                    L2a                                    LINE/L2           \(2804\)   3365   \(61\)    9

  2528    10.0      0.0       1.0       chr6:POLH:43572521+43581878   5271                 5581   \(3777\)    C                     AluSx1                                 SINE/Alu          \(4\)      308    1         10

  13      10.0      5.9       2.8       chr6:POLH:43572521+43581878   5582                 5615   \(3743\)    \+                    (TCTTTA)n                              Simple_repeat     1          36     \(0\)     11

  684     5.6       0.0       0.0       chr6:POLH:43572521+43581878   6162                 6233   \(3125\)    \+                    AluSq10                                SINE/Alu          1          72     \(241\)   12

  2510    10.3      0.0       0.0       chr6:POLH:43572521+43581878   6991                 7300   \(2058\)    \+                    AluSq2                                 SINE/Alu          1          310    \(3\)     13

  2679    7.0       0.0       0.0       chr6:POLH:43572521+43581878   7564                 7863   \(1495\)    C                     AluSq                                  SINE/Alu          \(13\)     300    1         14

  2503    8.4       0.7       0.0       chr6:POLH:43572521+43581878   8018                 8313   \(1045\)    C                     AluSg                                  SINE/Alu          \(11\)     299    2         15

  214     24.7      18.6      1.0       chr6:POLH:43572521+43581878   8598                 8683   \(675\)     \+                    MER5A                                  DNA/hAT-Charlie   2          102    \(87\)    16

  196     16.1      0.0       0.0       chr6:POLH:43572521+43581878   8684                 8714   \(644\)     \+                    MER5A                                  DNA/hAT-Charlie   \(159\)    189    \(0\)     17
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical features of Tunisian XP-V patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients    Affected patients   Sex   Age (years)       Age at onset of the 1st XP macules erythema (years)   Geographic\     Age at onset of 1st Tumor in years (Number of tumors)   Photophobia   Radiotherapy               Tumor post Radiotherapy                
                                                                                                                Origin                                                                                                                                                  
  ----------- ------------------- ----- ----------------- ----------------------------------------------------- --------------- ------------------------------------------------------- ------------- -------------------------- ------------------------- ------------ -----
  XPV6KE      1                   M     47 (died at 50)   4                                                     Kef             22 (6)                                                  20 (12)       ---                        +/−                       +++          +++

  XPV15GA     1                   F     18                4                                                     Gafsa           15 (2)                                                  16 (2)                                   +/−                                     

  XPV17-1 B   3                   F     17                4                                                     Bizerte         0                                                       0             0                          ---                                     

  XPV17-2 B   F                   11    4                 0                                                     0               0                                                       ---                                                                             

  XPV17-3 B   F                   4     5                 0                                                     0               0                                                       ---                                                                             

  XP18G       1                   F     43                4                                                     Gafsa           16 (8)                                                  21 (3)        KA                         +/−                       +++          +++

  XPV20G      3                   F     31                5                                                     Gafsa           ND (\>10)                                               ND (\>2)                                                           +++          \+

  XPV43-1     7                   M     ND                5                                                     Zaghouan        38 (8)                                                  23 (4)        KA and Actinic Keratosis   +/−                       \+ (local)   ---

  XPV43-2     F                   45?   5                 41 (1)                                                                                                                        +/−                                                                             

  XPV48G      1                   F     46                6                                                     Gafsa           0                                                       47 (1)                                   +/−                                     

  XPV53Z      1                   M     50                7                                                     Fahs Zaghouan   37 (4)                                                                                                                     \+ (local)   +/−

  XPV79-1     3 (1died)           F     13                3                                                     Tozeur/Gafsa    10 (3)                                                  ---           KA++                       +/−                                     

  XPV79-2     F                   18    3                                                                                       KA                                                      ---                                                                             

  XPV91-1     3                   F     29                6                                                     Tozeur                                                                                Actinic Keratosis          ---                                     

  XPV91-2                         F     21                6                                                                                                                                           ---                                                               

  XPV91-3                         F     24                6                                                                                                                                           ---                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCC: spino cell carcinoma; BCC: basal cell Carcinoma; KA: kerathoacantum; (+/−) moderate phenotype; (---) absence; (+++) several.

###### 

Complete list of primers used to gDNA amplification of exon 10 and its intronic boundaries.

  Name            Sequence 5′→3′                     Annealing Temperature (°C)   Suspected PCR products size (bp)   PCR Product size for XP-V patients (bp)
  --------------- ---------------------------------- ---------------------------- ---------------------------------- -----------------------------------------
  XPV10F          CCTGGTTCTTTTAATTTCCTCTCCTG         55                           459                                ---
  XPV10R          CATTTACCCTTTACCTCATTGAAGGAC                                                                        
                                                                                                                     
  XPV del 10 F    TCATTTGTGCTGTCCTGTTC               60                           3012                               ---
  XPV del 10 R    GGTTGCAGTGAGCGGAGATT                                                                               
                                                                                                                     
  Del ex10 LR-F   AGGTCCTCCCTAGTTACCCTATCACAGCAG     60                           4105                               ---
  Del ex10 LR-R   ACTACCTAACCCTGACTGACTTACCACTCTGG                                                                   
                                                                                                                     
  POLH10ΔF        AGTGGGTAGGTTTTGGTAGCTGTGGAAG       60                           9358                               *≈*6000 bp
  POLH10ΔR        GGACACACCCTGGATACTCTGTTGGTAA                                                                       
                                                                                                                     
  POLHFΔ          ACCTTGGAGTATAATTTCTGGGTCA          59                           5212                               *≈*1000 bp
  POLHRΔ          GTCATAAAGTTCCTCATTGTGTCTAA                                                                         
                                                                                                                     
  POLHdelF        CATGTGCTTGTTGGACATTTG              60                           4526                               *≈*500 bp
  POLHdelR        GGTTTCATGCTTTGGGACAG                                                                               
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